The companies' first offering is expected to be a multiplex respiratory disease panel.
More than 10 percent of individuals in an unselected population carried recurrent syndrome-associated CNVs or rare autosomal CNVs with potential ties to cognitive ability.
The company has also received approvals for various molecular diagnostics in the US and Canada in recent months.
The investigators used the technique to identify two novel secretome targets and then confirmed them to be elevated in the blood of women with cancer.
In a 6,000-patient study, Eskenazi Health will assess whether PGx testing improves outcomes and saves money in a community that doesn't usually have access to genomic advances.
In Genome Research this week: mitochondrial and nuclear gene fusions in cancer, role of genomic imprinting in tissue-specific gene expression, and more.
Maria Freire from the Foundation for the NIH calls for "politically popular pledges of support" for the NIH to turn into support for increased funding for the agency.
A Thomson Reuters analysis indicates that the life sciences, rather than the tech sector, are increasingly driving global innovation.
In PNAS this week: co-evolutionary signatures of insect hosts and bacterial symbionts, distinct transcript isoforms of high-grade ovarian cancer, and more.